Filing Details

Accession Number:
0001610717-24-000160
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-13 16:32:01
Reporting Period:
2024-03-11
Accepted Time:
2024-03-13 16:32:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1628171 Revolution Medicines Inc. RVMD () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1294192 A Margaret Horn C/O Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City CA 94063
Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-11 15,735 $4.09 158,202 No 4 M Direct
Common Stock Disposition 2024-03-11 15,735 $34.02 142,467 No 4 S Direct
Common Stock Acquisiton 2024-03-12 7,936 $4.09 150,403 No 4 M Direct
Common Stock Disposition 2024-03-12 7,936 $34.07 142,467 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-03-11 15,735 $0.00 15,735 $4.09
Common Stock Stock Option (Right to Buy) Disposition 2024-03-12 7,936 $0.00 7,936 $4.09
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
52,567 2023-03-13 2029-03-12 No 4 M Direct
44,631 2023-03-13 2029-03-12 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023.
  2. Includes 100,013 restricted stock units.
  3. This transaction was executed in multiple trades in prices ranging from $34.00 to $34.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. This transaction was executed in multiple trades in prices ranging from $34.00 to $34.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.